Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company
Profusa, a Nasdaq-listed digital health company, announced its Q2 2026 financial results, highlighting a net loss of $8.8 million for the quarter and progress on its option to acquire G3 Vision Labs, a commercial-stage diagnostics provider. The company executed a 4:1 reverse stock split, secured Series A Convertible Preferred Stock through debt exc…